Skip to main content
NewslettersWatchlist

Repare Therapeutics Inc(RPTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.82
Day High3.07
Open:2.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Business Wire
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Business Wire
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polฮธ ATPase Inhibitor
Business Wire
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Newswire.ca
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund
Newswire.ca
Amplitude Ventures Closes $263 Million Precision Medicine Venture Fund
AllPennyStocks.com
Small Cap Massively Bid Following Key Q1 Earnings Beat
The Globe and Mail
Market movers: Stocks seeing action on Tuesday - and why
Motley Fool
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
Business Wire
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
Business Wire
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
Business Wire
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
Business Wire
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) Investigation
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Business Wire
Repare Therapeutics Receives $1.5 Million (ยฅ200 million) Payment from Ono Pharmaceuticals
Business Wire
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Profile

Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.